Enfortumab Vedotin Plus Pembrolizumab vs Platinum-Based Chemotherapy in First-Line Metastatic Urothelial Carcinoma
The correct answer is B: At 3.5-year follow-up of EV-302, median overall survival was 33.6 months with enfortumab vedotin plus pembrolizumab (EV+P) versus 15.9 months with platinum-based chemotherapy 1.
Key Survival Outcomes from EV-302 Extended Follow-Up
The most recent data with 2.5-year median follow-up (approximately 3.5 years maximum follow-up) demonstrates:
- Median OS: 33.8 months with EV+P vs 15.9 months with chemotherapy (HR 0.51; 95% CI 0.43-0.61) 1
- OS gain: 17.9 months - this represents one of the largest survival improvements ever seen in first-line metastatic urothelial carcinoma
- Median PFS: 12.5 months vs 6.3 months (HR 0.48; 95% CI 0.41-0.57) 1
Why the Other Options Are Incorrect
Option A (Similar Overall Survival) - FALSE
Survival was dramatically different, not similar. The hazard ratio of 0.51 indicates a 49% reduction in risk of death with EV+P 1.
Option C (Lower Complete Response Rate) - FALSE
Complete response rates were HIGHER with EV+P, not lower:
- 29.1% complete response rate with EV+P vs 12.5% with chemotherapy 2
- Overall response rate: 67.7% vs 44.4% 2
Option D (Higher Toxicity Leading to Universal Discontinuation) - FALSE
Toxicity was actually LOWER with EV+P:
- Grade ≥3 treatment-related adverse events: 55.9% with EV+P vs 69.5% with chemotherapy 2
- Not all patients discontinued due to toxicity
- Safety profile remained consistent with extended follow-up 1
Clinical Implications Based on Guidelines
EV+P is now the ONLY preferred first-line regimen for metastatic urothelial carcinoma according to NCCN 2024 guidelines, receiving Category 1 designation in both cisplatin-eligible and cisplatin-ineligible settings 2. ESMO 2024 guidelines similarly support this combination with an ESMO-MCBS score of 4 3.
The Magnitude of Benefit
- 15.4-month absolute OS gain 3
- 6.2-month absolute PFS gain 3
- 5-year survival rate of 41.5% in cisplatin-ineligible patients 4
Quality of Life Considerations
Patients receiving EV+P showed:
- Numerical improvement in pain scores (least squares mean difference -0.38) 5
- Clinically meaningful improvements in Global Health Status/QOL (difference 2.54) 5
- Particularly significant benefit in patients with moderate-to-severe baseline pain 5
Important Caveats
While EV+P is preferred for most patients, platinum-based chemotherapy or other options remain appropriate when:
- Contraindications to EV or pembrolizumab exist
- Severe baseline peripheral neuropathy is present
- Uncontrolled diabetes (due to hyperglycemia risk with EV)
- Active autoimmune disease requiring immunosuppression
Patients ≥75 years receiving EV+P had higher fatal adverse reaction rates (7% vs 4% in younger patients), requiring enhanced monitoring 6.